Fundraising net proceeds go to COVID-19 Solidarity Response Fund for WHO

Clinical Trials During and After Covid-19

Current clinical trials were already stressed to function in a timely manner prior to Covid-19. Perpetual supply chain disruptions, in-person discontinuances, and constantly changing regulatory amendments make it very difficult for clinical trials to run effectively. With Covid-19, clinical trials are now completely disrupted. However, there are specific ways in which clinical trials can regain traction. These include developing virtual clinical trials and activating Emergency Use Authorizations (EUAs) by the Food and Drug Administration (FDA) to continue clinical trials in order for patients to have access to life saving emerging drugs.

Supply Chain Disruptions 

Currently, the U.S. is reliant on pharmaceutical manufacturing from other countries. In particular, the U.S. is largely dependent on China for important pharmaceuticals. These drugs include traditional small molecule medications but also emerging biologics. About 60% of shortages were attributed to supply disruptions due to manufacturing and/or quality problems in 2019”.2 From 2017 to 2018, the FDA reported an increase in the number of drug shortages. These shortages can be long and, in some cases, are delayed up to eight years.2 

COVID-19 was the tipping point into total chaos. Due to the pandemic, pharmaceutical drug distribution is in disarray. Labor shortages quarantined staff, and port disruptions are major contributors to the now severe disruption for supply chains. As many as 57 drugs made by large and small pharmaceutical companies are at risk due to Covid-19-induced restrictions in China.2 The most apparent disruption is, an active pharmaceutical ingredient, which is made in one country, must then be shipped to another for final formulation. Unfortunately, alternative manufacturing and distribution options are extremely expensive (up by 225%).2 Thus, as the Covid-19 pandemic is projected to continue into the near future, it is unclear how severe supply chain disruptions will impact on people’s well-being. 

Virtual Trials Ahead 

Virtual trials are a way to overcome the difficulties that Covid-19 has created. The virtual method is composed of approaches such as “the use of telemedicine, video/online meetings, telephone monitoring, wearable health, direct-to-patient delivery and sample pickup services, and decentralized laboratory facilities” 2  

There are a multitude of benefits that come with virtual clinical trials. One of the longer-term benefits is that virtual clinical trials “reduce unnecessary trips to hospitals, making trials more convenient for patients who are giving their time and energy.” 3 In turn, studies will gain increased important information due to the higher number of enrolled participants. As a result, virtual trials can potentially provide more meaningful and more statistically significant information compared to traditional trials limited to participants who can travel.  Over 50% of patients are more likely to participate in a trial if home care is offered. 

Another benefit of virtual clinical trials is cost. Typically, 40 to 60 % of a traditional clinical trial budget goes towards investigators.4 As virtual clinical trials will require fewer physical sites, fewer investigators to be hired is anticipated. On-site monitoring by nurses and staff makes up another 25 to 30% of the costs for traditional clinical trials. By reducing the number of investigators sites, the cost of on-site monitoring and management is significantly reduced. The use of remote-monitoring also reduces the cost for site monitors and all the travel, hourly rates, and expenses associated with all the personnel involved.4 Therefore, the ability of virtual trials to provide faster and more meaningful studies has the potential to not only be cost-effective but also accelerate the rate of drug approvals and patient access.

EUA May Save Current “brick and mortar” Clinical Trials 

An EUA permits the FDA to “help strengthen the nation’s public health protection against chemical, biological, radiological (CBRN) threats by facilitating the availability and use of medical countermeasures (MCM) required in public health emergencies.” 5 A significant amendment to the Federal Food, Drug, and Cosmetic Act was made in 2013, with the creation of the Pandemic and All-Hazards Preparedness Reauthorization (PAHPRA). The PAHPRA allows for “the FDA to waive otherwise applicable manufacturing requirements to accommodate emergency response needs.”6 The amendment also enables the FDA to dispense MCM’s during a CBRN emergency without requiring an individual prescription for each recipient of the MCM.6 Using this amendment, the FDA could potentially enable clinical trials to successfully complete trials for anti-Covid-19 therapies or vaccines faster and more efficiently, which will provide patients access to these much-needed medications. For clinical trials testing therapies focused on non-Covid-19-related illnesses, they could also be completed in a timely manner. Thus, the EUA is an effective tool the FDA can use to provide the necessary framework to guide clinicians and sponsors conducting clinical trials during the pandemic. 


The pandemic has triggered a necessary change in clinical trial design and management. Covid-19 has caused a significant disruption in providing everyday people and sick patients in hospitals with access to pharmaceuticals. However, virtual clinical trials may emerge as a viable alternative to in-person trials. Ongoing clinical trials may also benefit from the use of the EUA by the FDA. The degree of impact that Covid-19 has had on clinical trials is still ongoing and won’t be realized until this pandemic is over. But at least there are preparations in place to ensure the continued health of the global population.  

Bioinsider is hosting an intimate and informal Friday Roundtable Event on Friday, Nov. 6 to discuss some of these critical topics, “Addressing Bioanalysis in Clinical Trials during COVID-19” from 11:45 AM EST to 1:00 PM. You can sign up for FREE and join this discussion to share your thoughts here.


1 U.S. Dependence on Pharmaceutical Products From China. (2019, August 14). Council on Foreign Relations.

2 Alvaro, D. (2020, September 29). The COVID-19 Pandemic Magnifies Pharmaceutical Supply Chain Issues. Pharma’s Almanac.

3 Sukirti, K., & Newbould, C. (2020, August 25). Adapting clinical supply practices during Covid-19. European Pharmaceutical Manufacturer. 

4 Measuring The Financial Impact Of Remote (Digital) Clinical Trials. (2019, January 29). Clinical Leader. 

 5 Emergency Use Authorization. (2020, November 2). U.S. Food and Drug Administration. 

6 PAHPRA MCM Provisions. (2019, December 6). U.S. Food and Drug Administration.

Share on linkedin
Share on twitter
Share on facebook
Share on xing
Share on email

You may also be interested in...

James E. Crowe, Jr., MD,

Director, Vanderbilt Vaccine Center; Professor, Pediatrics and Pathology, Microbiology and Immunology, Ann Scott Carell Chair; Founder, IDBiologics

Dr. Crowe’s laboratory has a broad portfolio of work in the area of viral immunology and antibody sciences, with the goal to discover mechanisms of immunity important to developing new therapeutics and vaccines.

Dr. Crowe received his MD degree from the University of North Carolina at Chapel Hill, where he also completed his pediatrics residency. Following his clinical training, Dr. Crowe received five years of post-doctoral training in the laboratory of Infectious Diseases at the NIH. He completed infectious diseases fellowship training in 1996 at Vanderbilt and has run an independent laboratory at Vanderbilt since that time. He is currently Professor of Pediatrics and of Pathology, Microbiology and Immunology, and the Ann Scott Carell Chair, Vanderbilt University Medical Center. The laboratory’s work has been published in over 300 publications in high-quality science journals including CellScience and Nature, and leading medical journals including the New England Journal of Medicine and JAMA. Dr. Crowe was elected to the National Academy of Medicine in 2014 and the National Academy of Inventors in 2017. He has been the recipient of investigator awards from the March of Dimes, American Society for Microbiology, Pediatric Infectious Diseases Society, and Society for Pediatric Research. He was awarded the Judson Infectious Daland Prize of the American Philosophical Society, the Oswald Avery Award of the IDSA, the E. Mead Johnson Award for Excellence in Pediatrics, the Outstanding Investigator Award of the American Federation for Medical Research, the Norman J. Siegel Award of the American Pediatric Society, the Samuel Rosenthal Prize for Excellence in Academic Pediatrics, the Stanley J. Korsmeyer Award of American Society for Clinical Investigation, the Distinguished Medical Alumnus Award from UNC School of Medicine, Chapel Hill, NC. He is an elected Fellow of AAM, AAAS, ASCI, and AAP, IDSA, APS, and others. His research team was selected as the Best Academic Research Team at the 11th Annual Vaccine Industry Excellence Awards. He was awarded the inaugural 2019 Merck Future Insight Prize, a 1M Euro prize shared with Pardis Sabeti. 

He is the Founder of IDBiologics, Inc., an early-stage biotech company developing human monoclonal antibodies for infectious diseases.

Daniel Chen, MD, PhD

CMO, IGM Bioscience

Daniel S. Chen, MD, PhD, is the Chief Medical Officer for IGM Biosciences, and former Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.  He received a BS degree in Biology from the Massachusetts Institute of Technology (1990), a PhD in Microbiology & Immunology (1996), and MD (1998) from the University of Southern California. His PhD work and publications focused on “Early Events in Coronavirus Infection.”

Daniel completed an Internal Medicine Residency and Medical Oncology Fellowship at Stanford University (2003). He went on to complete a Post-doctoral fellowship with Mark Davis in Immunology, where he was a Howard Hughes Medical Institute Associate. He also ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003-2006. In that time, he studied human anti-cancer immune responses pre- and post-cancer vaccination and cytokine administration to determine why anti-tumor immune responses were not more clinically effective. He received a U19 grant to develop better immunologic tools to interrogate human immune responses and ultimately patented the MHC cellular microarray to detect and functionally characterize antigen-specific T cell states.

He continued as Adjunct Clinical Faculty at Stanford from 2006-2016, where he cared for melanoma patients. At Genentech from 2006-2018, Daniel focused on the clinical development of anti-angiogenic and immune-modulatory targeted therapies in both early and late development, as well as the diagnostic tools to aid their development. This included leading the clinical development for atezolizumab, a PD-L1 inhibitor, from the time the program was in research through IND, Phase I, Phase II, Phase III, to filing and approvals in multiple indications worldwide. At IGM, Daniel focuses on the development of novel engineered multivalent and multispecific therapeutics. He is a reviewer for Nature, Immunity, and Clinical Cancer Research, serves on the Board of Directors for SITC, co-chair of the CRI cancer Immunotherapy consortium, gave the keynote presentation at the AACR NCI EORTC Annual Meeting 2014 and presented at the US Congressional Briefing on Immuno Oncology in 2017. He has continued to publish with academic and industry collaborators in the field of cancer immunotherapy, including the often-referenced Chen and Mellman manuscripts, “Elements of cancer immunity and the cancer-immune set point” and “Oncology meets Immunology: The Cancer-Immunity Cycle.”

Imre Berger

Founding Director, Max Planck Bristol Centre; Chair in Biochemistry and Chemistry; University of Bristol UK

Imre Berger was trained as a biochemist and synthetic biologist at Leibniz University and Medical School (MHH) in Hannover (Germany), at MIT (Cambridge, USA), and at ETH Zurich (Switzerland). Imre’s team develops enabling methods for DNA delivery and genome engineering, engineers synthetic vaccines and nanosensors and researches the structure and mechanism of multiprotein complexes in human health and disease. After Group Leader posts at ETH (2005) and EMBL (2007), Berger joined Bristol as Full Professor of Biochemistry (2014) with a joint appointment in Chemistry (2019). He is Founding Director of the Max Planck Centre for Minimal Biology in Bristol, Director of the BBSRC/EPSRC research center for synthetic biology BrisSynBio and Co-director of the Bristol Biodesign Institute BBI.

Imre Berger holds international patents for DNA and protein technologies, co-founded three biotech companies, and received numerous distinctions, notably the Swiss Technology Award, the W.A. DeVigier Foundation Award, and a Wellcome Trust Senior Investigator Award for his innovative research. Since 2019, he is an Investigator of the European Research Council (ERC).

Prof. Berger has participated in leading roles in numerous European Commission (EC) projects, including the pan-European structural biology infrastructure INSTRUCT. He has been Coordinator of the EC FP7 HEALTH ComplexINC project enhancing production tools for complex biologics in academic and industrial R&D (2011-2016) and is partner in the EPSRC funded Innovative Future Vaccine Manufacturing Research Hub.

Sina Bavari, PhD

CSO, Edge BioInnovation Consulting and Management; former CSO, Scientific Director US Army Medical Research Institute of Infectious Diseases (USAMRIID)

Dr. Sina Bavari is the co-founder of Healion Bio. He is one of the lead (non-gov) scientific adviser to the World Health Organization on SARSCoV-2. He has spent over 30 years developing rapid response diagnostics, prophylaxis, therapeutics, and vaccines for some of the world’s deadliest infectious diseases. Prior to co-founding Healion Bio, Dr. Bavari founded Edge BioInnovation Consulting and Mgt. and was the Chief Scientific Officer and Scientific Director at USAMRIID (US Army Research Institute of Infectious Diseases), where he spent over twenty years leading the discovery and development of vaccines, therapeutics, and diagnostics or diseases such as SARS and MERS CoVs, Ebola, Marburg, Zika, Smallpox, Sudan, Nipah, alpha viruses, Anthrax and many others. He has worked extensively with the FDA to successfully develop clinically proven countermeasures for many so-called envelope viruses like SARS-CoV-2. Dr. Bavari has contributed to ~20 drug development candidates such as Remdesivir, 30 patents, and many IND filings. He has trained over 70 scientists and managed over 500 scientists and supporting staff. His work has resulted in over 350 publications in many of the leading scientific journals including Nature, Nature Medicine, Cell, Cell Hosts, New England Journal of Medicine and many others. He has degrees from USC, and the University of Nebraska where he received his PhD in Immunotoxicology and Pharmaceutical Science.

Therapeutics Pipeline for COVID-19

Get the latest updates, interviews and receive special offers

Pre-register Today!

Ralph Rogers, MD

Assistant Professor of Medicine, Clinician Educator, Infectious Diseases, Warren Alpert Medical School of Brown University

Ralph Rogers, MD is an infectious disease specialist at the Lifespan Cancer Institute. He earned his medical degree from The Warren Alpert Medical School of Brown University where he also completed his residency and fellowship in infectious diseases. Dr. Rogers is Assistant Professor of Medicine, Clinician Educator Division of Infectious Diseases Warren Alpert Medical School of Brown University. He is a member of the Infectious Diseases Society of America (IDSA), the American Society for Microbiology (ASM) and the American Society of Transplantation (AST).

John Sninsky, PhD

Consultant, Translational Sciences

John J. Sninsky, PhD is a translational medicine consultant with deep understanding of diagnostics and diagnostics paired with medicine intervention. John has served in senior management positions in small and large CLIA service laboratories and in vitro diagnostic kit companies including Cetus, Roche Molecular Systems, Celera, Quest and CareDx. He was a member of the pioneering Cetus team that developed and optimized PCR technology for research and diagnostic use; specifically, the virology team developed the HIV, HTLV, HPV, HCV and HBV PCR assays. John put in place a surveillance initiative for viral variants and presented at the first FDA PMA advisory meeting for HIV PCR approval.

Timothy J. O’Leary, MD, PhD

Adjunct Professor, Pathology, University of Maryland School of Medicine; Former Chief Research and Development Officer, Veterans Affairs

Timothy O’Leary, MD, is Adjunct Professor of Pathology at the University of Maryland and served as Chief Research and Development Officer (CRADO) of the Department of Veterans Affairs from 2013-2015. He holds a doctorate in physical chemistry from Stanford University and a medical degree from the University of Michigan.

He is certified in anatomic pathology by the American Board of Pathology and in molecular genetic pathology by the American Board of Pathology and the American Board of Medical Genetics. Prior to his VA service, O’Leary chaired the Department of Cellular Pathology and Genetics at the Armed Forces Institute of Pathology for more than 15 years. He joined VA in 2004 and served as Director of Biomedical Laboratory Research and Development, Director of Clinical Sciences Research and Development, and Deputy CRADO prior to his appointment as CRADO. O’Leary also served as a reserve member of the Public Health Service Commissioned Corps from 1979 to 2010, serving two tours on active duty. His research interests include genomics, proteomics, and ultrasensitive detection of biological toxins. He has served on numerous federal panels and advisory committees, including the Health and Human Services Clinical Laboratory Improvement Advisory Committee and the Food and Drug Administration Hematology and Devices Panel. O’Leary, the holder of four patents, has authored or co-authored more than 190 journal articles and numerous book chapters and technical reports. He is a past president of the Association for Molecular Pathology and served as editor-in-chief for the Journal of Molecular Diagnostics.